EM
EMBC.US Embecta Corp
- Market cap
- USD 366M
- P/E
- 4.4x
- P/B
- 2.61x
- ROE
- -
- Dividend yield
- 9.56%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is EMBC.US undervalued?
Graham numberEMBC.US trades 28.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Embecta Corp fundamental analysis
No fundamental analysis for Embecta Corp yet.
Embecta Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Embecta Corp
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded …
Full company profileEmbecta Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Embecta Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.11B | 1.09B | 1.17B | 1.13B | 1.12B | 1.12B | 1.08B | 1.01B |
| Gross Profit | 786M | 763M | 800M | 775M | 750M | 729M | 680M | 605M |
| Operating Income | 502M | 487M | 492M | 378M | 230M | 174M | 329M | 252M |
| EBITDA | 536M | 524M | 533M | 335M | 245M | 193M | 284M | 274M |
| Net Income | 432M | 428M | 415M | 224M | 70.4M | 78.3M | 95.4M | 81.5M |
| EPS | 7.58 | 7.50 | 7.30 | 3.92 | 1.22 | 1.34 | 1.62 | 1.39 |
| Balance Sheet | ||||||||
| Total Assets | 745M | 738M | 788M | 1.09B | 1.21B | 1.29B | 1.09B | 1.27B |
| Total Liabilities | 126M | 166M | 194M | 1.98B | 2.04B | 2.02B | 1.74B | 1.88B |
| Shareholders' Equity | 577M | 572M | 594M | -891M | -822M | -738M | -651M | -613M |
| Cash & Short-term Investments | - | - | 0.00 | 331M | 327M | 268M | 226M | 215M |
| Total Debt | - | 5.00M | 4.10M | 1.64B | 1.64B | 1.61B | 1.43B | 1.50B |
| Cash Flow | ||||||||
| Operating Cash Flow | 505M | 499M | 456M | 412M | 67.7M | 35.7M | 192M | 120M |
| Capital Expenditure | 69.0M | 41.9M | 39.0M | 24.0M | 26.5M | 15.8M | 9.30M | 2.93M |
| Free Cash Flow | 436M | 457M | 417M | 388M | 41.2M | 19.9M | 182M | 117M |
| Ratios | ||||||||
| ROE | 74.9% | 74.8% | 69.8% | - | - | - | - | - |
| ROA | 58.0% | 57.9% | 52.6% | 20.6% | 5.8% | 6.1% | 8.7% | 6.4% |
| Net Profit Margin | 39.0% | 39.4% | 35.6% | 19.8% | 6.3% | 7.0% | 8.8% | 8.1% |
| Debt to Equity | - | 0.01x | 0.01x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Embecta Corp dividends
- Dividend yield
- 9.56%
- Forward dividend
- 0.04 USD
- Payout ratio
- 36.7%
- Ex-dividend date
- Aug 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 35.0M | 0.59 | 36.7% |
| 2024 | USD 34.5M | 0.59 | 44.1% |
| 2023 | USD 34.4M | 0.60 | 48.9% |
| 2022 | USD 8.60M | 0.15 | 3.8% |
| 2021 | USD 8.60M | 0.15 | 2.1% |
| 2020 | USD 8.60M | 0.15 | 2.0% |
| 2019 | USD 8.60M | 0.15 | 2.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Embecta Corp
- Insiders 3.45%
- Institutions 93.17%
- Public & others 3.38%
- Shares outstanding 56.7M
- Free float 54.8M
Top funds holding EMBC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AMG Yacktman I | 3.50M | 6.18% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.83M | 3.23% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.55M | 2.73% | 0.00% | Oct 2026 |
| Columbia Small Cap Value Discv A | 1.38M | 2.44% | +0.73% | Sep 2026 |
| Royce Small-Cap Trust | 596K | 1.05% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 568K | 1.00% | 0.00% | Oct 2026 |
| Pacer US Small Cap Cash Cows 100 ETF | 541K | 0.95% | +0.23% | Oct 2026 |
| IG Mackenzie Global Health Care B | 479K | 0.84% | +25.99% | Jul 2026 |
| Schwab Fundamental U.S. Small CompanyETF | 436K | 0.77% | 0.00% | Oct 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 369K | 0.65% | +28.07% | Sep 2026 |
| Vanguard Russell 2000 ETF | 348K | 0.61% | +0.99% | Sep 2026 |
| PIMCO RAE US S Instl | 342K | 0.60% | +48.14% | Jun 2026 |
| Fidelity Small Cap Index | 320K | 0.56% | -53.29% | Aug 2026 |
| WisdomTree US SmallCap Dividend ETF | 304K | 0.54% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 296K | 0.52% | +0.24% | Oct 2026 |
| Vanguard US Value Factor ETF | 279K | 0.49% | +15.71% | Sep 2026 |
| Fidelity Extended Market Index | 271K | 0.48% | +104.43% | Sep 2026 |
| SQUAD Point Five I | 246K | 0.43% | +0.02% | Jul 2026 |
| Columbia VP Small Cap Value Discovery 1 | 239K | 0.42% | 0.00% | Sep 2026 |
| Vanguard Global Value Factor ETF CAD | 216K | 0.38% | +76.78% | Sep 2026 |
Top institutions holding EMBC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 4.60M | 8.12% | -49.82% | Jun 2026 |
| Yacktman Asset Management Co | 4.32M | 7.62% | +17.54% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.56M | 4.51% | -0.27% | Jun 2026 |
| Deerfield Management Co | 2.53M | 4.47% | 0.00% | Jun 2026 |
| Jefferies Financial Group Inc | 2.36M | 4.16% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 2.04M | 3.60% | +154.94% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.00M | 3.52% | +227.44% | Jun 2026 |
| State Street Corp | 1.61M | 2.84% | -36.74% | Jun 2026 |
| Geode Capital Management, LLC | 1.59M | 2.81% | +8.79% | Jun 2026 |
| Brigade Capital Management LP | 1.52M | 2.68% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.16M | 2.05% | +55.26% | Jun 2026 |
| Krensavage Asset Management, LLC | 1.14M | 2.00% | +54.40% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.10M | 1.94% | -28.58% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.07M | 1.89% | -10.26% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 1.03M | 1.81% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 977K | 1.72% | +194.50% | Jun 2026 |
| Millennium Management LLC | 946K | 1.67% | -40.66% | Jun 2026 |
| Acadian Asset Management LLC | 861K | 1.52% | +186.90% | Jun 2026 |
| UBS Group AG | 829K | 1.46% | +92.79% | Jun 2026 |
| D. E. Shaw & Co LP | 650K | 1.15% | +22.12% | Jun 2026 |
Embecta Corp company profile
- Company name
- Embecta Corp
- Ticker
- EMBC.US
- Exchange
- USA Stocks
- Listed since
- Apr 1, 2022
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,850
- Fiscal year end
- September
- Address
- 300 Kimball Drive, Parsippany, NJ, United States, 07054
- Phone
- 862 401 0000
- Website
- embecta.com
About Embecta Corp
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Embecta Corp management
10- Mr. Devdatt Kurdikar Ph.D.President, CEO & Chairman · born 1969
- Mr. Jacob P. ElguiczeSenior VP & CFO · born 1973
- Mr. Jeffrey Z. MannSenior VP, General Counsel, Head of Business Development & Corporate Secretary · born 1972
- Ms. Jean M. CasnerSenior VP & Chief Human Resources Officer · born 1958
- Mr. Shaun CurtisSenior Vice President of Global Manufacturing & Supply Chain · born 1970
- Mr. Anthony M. RothVP, Chief Accounting Officer & Corporate Controller · born 1973
- Mr. Pravesh KhandelwalVP & Head of Investor Relations
- Ms. Ginny BlockiSenior Vice President of Strategy
- Mr. Tom BlountSenior VP & President of North America · born 1974
- Mr. Slobodan RadumiloSenior VP & President of International · born 1971